Drug-Screening and Resistance Hub (CRUSH)
Established in partnership with LifeArc, CRUSH strives to address pandemic preparedness within the globally renowned MRC - University of Glasgow Centre for Virus Research (CVR), providing access to the specialist knowledge and facilities of the CVR for partners in all sectors of industry and academia.
You can find information about CRUSH, the services they provide and the facilities they have access to on the CRUSH website: https://www.cvrcrush.co.uk/
You can watch our overview video here:
CRUSH has both the infrastructure and expertise to take the initial in vitro screening of antiviral compounds through to functional studies and on to pre-clinical animal models for efficacy evaluation of promising candidates.
CRUSH is a fully integrated hub with access to bespoke biocontainment facilities and the expertise to support small animal model studies of high consequence viruses, including SARS-CoV-2. Proximity to the CVR’s virology expertise, viral genomics and computational biology capabilities further strengthens the CRUSH offering.
The CVR provides an ideal environment for both therapeutic screening and deepening of our understanding of the molecular biology of SARS-CoV-2 and the emerging phenomenon of resistance to anti-virals.
“Our partnership with the CVR to establish CRUSH will provide the virology research community in the UK with much-needed infrastructure and facilities to progress essential research for Covid-19 drug development, other anti-viral therapies and diagnostics, towards patients.” Michael Dalrymple, Executive Director Diagnostics and Science Foresight at LifeArc
